Albireo Pharma Inc - ESG Rating & Company Profile powered by AI
This assessment of Albireo Pharma Inc employs intelligence from across the web and also from available documents by Albireo Pharma Inc. This report of Albireo Pharma Inc was assembled by All Street Sevva using proprietary AI. Full Sustainability analysis of Albireo Pharma Inc are reached by signing up for free.
Albireo Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 3.2, social score of 3.2 and governance score of 6.7.
4.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1121 | Protagonist Therapeutics Inc | 4.8 | High |
| 1121 | Shanghai Medicilon Inc | 4.8 | High |
| 1156 | Albireo Pharma Inc | 4.7 | High |
| 1156 | Adaptimmune Therapeutics PLC | 4.7 | High |
| 1156 | Arcticzymes Technologies ASA | 4.7 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Albireo Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Albireo Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Albireo Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Albireo Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Albireo Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Albireo Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Albireo Pharma Inc offer flexible work?
Sign up for free to unlockDoes Albireo Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Albireo Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Albireo Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Albireo Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Albireo Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Albireo Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Albireo Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Albireo Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Albireo Pharma Inc disclose water use targets?
Sign up for free to unlockDoes Albireo Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Albireo Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Albireo Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Albireo Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Albireo Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Albireo Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Albireo Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Albireo Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Albireo Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Albireo Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Albireo Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Albireo Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Albireo Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Albireo Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Albireo Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes Albireo Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Albireo Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Albireo Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes Albireo Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Albireo Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Albireo Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.